17 studies found for:    ponatinib
Show Display Options
Rank Status Study
1 Active, not recruiting Ponatinib - 2nd Line Therapy
Condition: Leukemia
Intervention: Drug: Ponatinib
2 Suspended Ponatinib for Squamous Cell Lung and Head and Neck Cancers
Condition: Non-Small Cell Lung Cancer, Head and Neck Cancer
Intervention: Drug: ponatinib
3 Not yet recruiting Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Condition: Endometrial Neoplasms
Intervention: Drug: Ponatinib
4 Recruiting A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions: Drug: ponatinib - Phase 1;   Drug: ponatinib - Phase 2
5 Recruiting Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Conditions: Adenocarcinoma of the Lung;   Extensive Stage Small Cell Lung Cancer;   Limited Stage Small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Ponatinib
6 Active, not recruiting Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
Condition: Leukemia
Intervention: Drug: Ponatinib
7 Approved for marketing Expanded Access Program of Ponatinib
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: ponatinib
8 Active, not recruiting PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Ph+ Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Ponatinib (AP24534)
9 Suspended Phase II Front-line Treatment of Adult Affected of Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (ALL) With Ponatinib.
Conditions: Philadelphia Positive;   BCR-ABL Positive;   Acute Lymphoblastic Leukemia
Intervention: Drug: Ponatinib
10 Suspended Ponatinib in Advanced NSCLC w/ RET Translocations
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ponatinib
11 No longer available Compassionate Use Ponatinib
Conditions: Philadelphia Chromosome Positive (Ph+) Leukemias;   Chronic Myeloid Leukemia
Intervention: Drug: Ponatinib
12 Active, not recruiting Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
13 Recruiting Ponatinib for Advanced Medullary Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention: Drug: Ponatinib
14 Recruiting A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: GIST
Intervention: Drug: ponatinib
15 Terminated Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib;   Drug: imatinib (Gleevec/ Glivec)
16 Active, not recruiting Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Conditions: Chronic Myelogenous Leukemia;   Hematologic Malignancies
Intervention: Drug: Ponatinib, AP24534
17 Recruiting Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia
Interventions: Device: in vitro kinase inhibitor assay;   Drug: Sunitinib;   Drug: Dasatinib;   Drug: Nilotinib;   Drug: Sorafenib;   Drug: Ponatinib

Indicates status has not been verified in more than two years